Table 2.
Comparison of glucose variability in the two groups between baseline and endpoint
| Variables | Dapagliflozin (n = 14) | DPP-4 inhibitors (n = 15) | Change difference between groups p value | ||||
|---|---|---|---|---|---|---|---|
| Baseline | Endpoint | Mean change (95% CI) | Baseline | Endpoint | Mean change (95% CI) | ||
| MAGE (mg dL−1) | 86.0 ± 29.4 | 91.0 ± 34.2 | 5.0 (−11.6 to 21.7) | 89.8 ± 24.1 | 105.0 ± 30.9 | 15.2 (−3.8 to 34.3) | 0.39 |
| 24-h mean blood glucose (mg dL−1) | 147.4 ± 26.6 | 144.6 ± 22.7 | −2.8 (−13.6 to 8.0) | 150.5 ± 21.8 | 155.2 ± 26.1 | 4.7 (−7.1 to 16.4) | 0.32 |
| 24-h SD values glucose levels | 35.3 ± 11.4 | 39.1 ± 11.7 | 3.9 (−1.7 to 9.4) | 37.5 ± 8.5 | 43.6 ± 11.7 | 6.1 (0.0 to 12.3) | 0.56 |
| 24-h AUC > 180 (mg dL−1 day−1) | 6.9 ± 6.3 | 6.9 ± 6.1 | −0.1 (−4.0 to 3.9) | 7.3 ± 6.3 | 11.6 ± 10.0 | 4.2 (0.6 to 7.8) | 0.09 |
| 24-h AUC < 70 (mg dL−1 day−1) | 0 (0–0) | 0.1 (0–0.3) | 0 (−0.5 to 1.0) | 0 (0–0.1) | 0 (0–0.1) | 0.0 (−1.0 to 0.5) | 0.21† |
| Nighttime AUC < 70 (mg dL−1 day−1) | 0 (0–0) | 0 (0–0.4) | 0 (0 to 1.0) | 0 (0–0) | 0 (0–0) | 0.0 (−0.2 to 1.0) | 0.05† |
| The total insulin dose (U kg−1) | 0.23 ± 0.19 | 0.23 ± 0.21 | 0.00 (−0.03 to 0.02) | 0.25 ± 0.13 | 0.25 ± 0.13 | 0.00 (−0.01 to 0.01) | 0.64 |
Baseline data are presented as the mean ± SD or median (25–75% CI). p values: mean changes from baseline to the end of the study between the Dapagliflozin group and the DPP-4 inhibitors group. † Mann–Whitney U test
MAGE mean amplitude of glycemic excursions, 24-h all day, SD standard deviation, AUC area under the curve, nighttime 00:00 to 08:00 h